New GlyT1 inhibitor BI 425809 is included in China's breakthrough treatment varieties

Source: Guanlan Pharmaceutical

On June 29, Boehringer Ingelheim announced that BI 425809 has been included in the Drug Evaluation Center (CDE) of the State Drug Administration of China as a breakthrough therapy for the treatment of cognitive disorders related to schizophrenia ( CIAS)

BI 425809 is a new drug in the central nervous pipeline of Boehringer Ingelheim.

Currently, BI 425809 is carrying out a global phase 3 clinical trial, and China is also participating in it simultaneously

A randomized, double-blind, placebo-controlled phase 2 clinical trial study showed that: according to the dose assessment model, compared with placebo, the MCCB overall composite T score of the 10 mg and 25 mg dose groups (a type of schizophrenic neuropathy) Cognitive efficacy assessment test) has the largest change from baseline, and the incidence of adverse reactions in each group is equivalent

According to reports, Boehringer Ingelheim has planned to initiate a phase 3 clinical trial of BI 425809 to evaluate the safety and effectiveness of the drug in improving the cognition of adult patients with schizophrenia

According to the World Health Organization, the lifetime prevalence of schizophrenia worldwide is about 1%, and about 80% of patients have cognitive impairments of varying degrees